000101126 001__ 101126
000101126 005__ 20180317092327.0
000101126 013__ $$d20060914$$bWO$$cA3$$aWO2006066439
000101126 013__ $$d20060629$$bWO$$cA2$$aWO2006066439
000101126 013__ $$d20060628$$bEP$$cA1$$aEP1674573
000101126 02470 $$2EPO Family ID$$a34932426
000101126 02470 $$a6.0549$$2TTO
000101126 037__ $$aPATENT
000101126 245__ $$aRNA-sequence or nucleoside/nucleotide analogues and method for producing the analogues
000101126 260__ $$c2006
000101126 269__ $$a2006
000101126 336__ $$aPatents
000101126 520__ $$aNucleic acid sequence analogues, in particular tRNA analogues comprising in the place of a 3'-terminal adenosine a 3'-terminal 2'-deoxy-2'-thioadenosine are able to react site-specifically with weakly activated amino acid derivatives (e.g. phenylthioesters of amino acids), thereby connecting the amino acid to the 2'-thiol-group of the 3'-terminal thioadenosine via a thioester bond. A fast and thermodynamically favored intramolecular transesterification reaction leads then to the formation of the corresponding 3'-O-acyl-derivative. A correspondingly modified tRNA is an active analogue of an aminoacylated tRNA and allows introduction of the amino acid bound thereto into proteins. The aminoacylated tRNA analogue according to the invention can be isolated in pure form under acidic conditions (pH 5.0). At pH 7.4 and 25 DEG C it is found to have a half-life of 25 min, which compares well with the half-life of 40 min for the corresponding native compound.
000101126 700__ $$0240732$$g145837$$aPitsch, Stefan
000101126 700__ $$aMeyyapan, Muthuppalaniappan
000101126 700__ $$aPorcher, Sébastien$$g148140$$0245089
000101126 909C0 $$0252378$$pLCAN
000101126 909C0 $$0252085$$pTTO$$xU10021
000101126 937__ $$aLCAN-PATENT-2007-002
000101126 973__ $$sPUBLISHED$$aEPFL
000101126 980__ $$aPATENT